1h Free Analyst Time
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes. Speak directly to the analyst to clarify any post sales queries you may have.
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 2 and 3 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Acute Lymphoblastic Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Diffuse Large B-Cell Lymphoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection, Malignant Glioma, Mantle Cell Lymphoma, Medulloblastoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma and Recurrent Medulloblastoma.
The latest report Human cytomegalovirus 65 kDa Phosphoprotein - Drugs In Development, 2022, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
- The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development
- AlphaVax Inc
- Helocyte Biosciences Inc
- Hookipa Pharma Inc
- Immunomic Therapeutics Inc
- Moderna Inc
- VBI Vaccines Inc
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles
- AVX-601 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cytomegalovirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cytomegalovirus vaccine 1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ITI-1000 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ITI-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mRNA-1443 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Triplex - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- VBI-1901 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products
- Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones
- Featured News & Press Releases
- Jun 22, 2022: VBI vaccines receives U.S. FDA Orphan Drug Designation for VBI-1901 for the treatment of glioblastoma
- Jun 06, 2022: VBI Vaccines presents updated phase 2a tumor response and overall survival data for VBI-1901 in recurrent GBM at the 2022 ASCO Annual Meeting
- Apr 28, 2022: VBI Vaccines announces data from VBI-1901 in recurrent glioblastoma patients selected for poster discussion at the 2022 ASCO Annual Meeting
- Apr 14, 2022: Immunomic Therapeutics to participate at World Vaccine Congress Washington 2022
- Jan 26, 2022: VBI Vaccines to participate in the B. Riley Securities 2022 Oncology Investor Conference
- Jan 06, 2022: Immunomic Therapeutics CBO to present at the 14th Annual Biotech Showcase Event
- Dec 17, 2021: Fortress and Helocyte begin Phase II trial of cytomegalovirus vaccine
- Dec 01, 2021: VBI Vaccines to present new overall survival data from phase 2a study in recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
- Nov 30, 2021: Immunomic Therapeutics announces open enrollment for RENEW clinical study of CMV RNA-pulsed dendritic cell vaccine for the treatment of newly-diagnosed glioblastoma patients
- Nov 18, 2021: Immunomic Therapeutics presents clinical data from ATTAC studies in GBM at the 2021 Society for Neurology (SNO) Annual Meeting
- Nov 09, 2021: HOOKIPA announced Phase 2 data on HB-101
- Jun 08, 2021: VBI Vaccines granted FDA fast track designation for VBI-1901 for the treatment of recurrent GBM
- May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
- Feb 02, 2021: Immunomic Therapeutics’ CEO to present at the BIO CEO & Investor Digital Conference
- Jan 05, 2021: Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AlphaVax Inc, 2022
- Pipeline by Helocyte Biosciences Inc, 2022
- Pipeline by Hookipa Pharma Inc, 2022
- Pipeline by Immunomic Therapeutics Inc, 2022
- Pipeline by Moderna Inc, 2022
- Pipeline by VBI Vaccines Inc, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AlphaVax Inc
- Helocyte Biosciences Inc
- Hookipa Pharma Inc
- Immunomic Therapeutics Inc
- Moderna Inc
- VBI Vaccines Inc
